Similarly, another study evaluated MEDI9197, a TLR7/8 agonist, when administered alone or in combination with durvalumab and/or palliative radiation in subjects with solid tumors, highlighting the exploration of TLR agonists in cancer therapy [73,79]. Here, TLR7 is linked to cancer.